RxDoctor Payments Data

Christopher Kobet, MD

Neurology · Grand Rapids, MINPI 1609087907

Payments from drug & device makers

$215in general payments, 2019–2025

Across 11 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$42
  • Acorda Therapeutics, Inc$41
  • Cala Health, Inc.$27
  • Adamas Pharmaceuticals, Inc.$20
  • Bristol Myers Squibb$20
  • E.r. Squibb & Sons, L.L.C.$19
  • plus $47 from 3 others

What the payments were for

  • Speaking & faculty fees$4119%
  • Food & beverage$15572%
  • Education$199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$215 in reported general payments places this provider in the 25th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$34,385
Medicare patients
212
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$175,630
Tetrabenazine66$94,264
Carbidopa-LevodopaCarbidopa/Levodopa1,269$84,128
AustedoDeutetrabenazine16$79,225
RytaryCarbidopa/Levodopa47$78,893
Carbidopa67$32,129
Primidone609$19,712
Carbidopa-Levodopa ErCarbidopa/Levodopa240$13,295
Emgality SyringeGalcanezumab-Gnlm12$8,805
Propranolol Hcl ErPropranolol Hcl161$7,294
Entacapone20$5,388
Propranolol Hcl116$2,441
Gabapentin146$2,303
AmantadineAmantadine Hcl57$2,293
Donepezil Hcl129$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$18$78,89347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 652 neurology providers in Michigan.

Other neurology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →